Dara-SVD vs. Dara-RVD
A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 70 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- Selective Inhibiton of Nuclear Export (SINE), Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1823
- NCT Identifier
- NCT06169215
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.